{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:33:29Z","timestamp":1740112409514,"version":"3.37.3"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.talanta.2024.127111","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T05:55:55Z","timestamp":1730267755000},"page":"127111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A liquid chromatography - Tandem mass spectrometry method for determination of ocrelizumab in serum of patients with multiple sclerosis"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-5462","authenticated-orcid":false,"given":"Patrik","family":"Matlak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Brozmanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Sistik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denisa","family":"Moskorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-754X","authenticated-orcid":false,"given":"Ivana","family":"Kacirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Hradilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-0455","authenticated-orcid":false,"given":"Milan","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2024.127111_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.talanta.2024.127111_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cca.2015.01.035","article-title":"Role of amyloid-\u03b2 CSF levels in cognitive deficit in MS","volume":"449","author":"Gentile","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.talanta.2024.127111_bib3","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg","year":"2012","journal-title":"Pharmacy and therapeutics"},{"issue":"3","key":"10.1016\/j.talanta.2024.127111_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.talanta.2024.127111_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577359","article-title":"Analysis of plasma protein biomarkers in childhood onset multiple sclerosis","volume":"348","author":"Solmaz","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.talanta.2024.127111_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120074","article-title":"Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage","volume":"432","author":"Menascu","year":"2022","journal-title":"J. Neurol. Sci."},{"author":"Tafti","key":"10.1016\/j.talanta.2024.127111_bib7"},{"issue":"9","key":"10.1016\/j.talanta.2024.127111_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.talanta.2024.127111_bib9","article-title":"Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurology: Neuroimmunol. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.talanta.2024.127111_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ana.26534","article-title":"Ocrelizumab concentration is a good predictor of SARS\u2010CoV\u20102 vaccination response in patients with multiple sclerosis","volume":"93","author":"van Kempen","year":"2023","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.talanta.2024.127111_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1352458512460604","article-title":"Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis","volume":"19","author":"Vennegoor","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1016\/j.talanta.2024.127111_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.talanta.2024.127111_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/039463200702000217","article-title":"A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application","volume":"20","author":"Montagna","year":"2007","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"12","key":"10.1016\/j.talanta.2024.127111_bib14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2004.04.003","article-title":"Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay","volume":"28","author":"Jilani","year":"2004","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.talanta.2024.127111_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40263-021-00895-w","article-title":"Population pharmacokinetic\u2013B cell modeling for ofatumumab in patients with relapsing multiple sclerosis","volume":"36","author":"Yu","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.talanta.2024.127111_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jmsacl.2022.07.004","article-title":"Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry","volume":"25","author":"Hallin","year":"2022","journal-title":"Journal of Mass Spectrometry and Advances in the Clinical lab"},{"key":"10.1016\/j.talanta.2024.127111_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.342789","article-title":"High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS\/MS","author":"Hallin","year":"2024","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.talanta.2024.127111_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115542","article-title":"Liquid chromatography-tandem mass spectrometry method for determination of natalizumab in serum and cerebrospinal fluid of patients with multiple sclerosis","volume":"234","author":"Matlak","year":"2023","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2024.127111_bib19","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1007\/s00216-017-0488-2","article-title":"Quantitative LC\/ESI-SRM\/MS of antibody biopharmaceuticals: use of a homologous antibody as an internal standard and three-step method development","volume":"409","author":"Osaki","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2024.127111_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.462840","article-title":"Middle-up quantification of therapeutic monoclonal antibodies in human plasma with two dimensional liquid chromatography high resolution mass spectrometry: adalimumab as a proof of principle","volume":"1665","author":"El Amrani","year":"2022","journal-title":"J. Chromatogr. A"},{"issue":"6","key":"10.1016\/j.talanta.2024.127111_bib21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1515\/cclm-2019-0862","article-title":"Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation","volume":"58","author":"Cradic","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.talanta.2024.127111_bib22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.intimp.2015.07.007","article-title":"Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC\u2013MS\/MS","volume":"28","author":"Willrich","year":"2015","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.talanta.2024.127111_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chroma.2016.05.070","volume":"1454","author":"El Amrani","year":"2016","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.talanta.2024.127111_bib24","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41598-017-02821-x","article-title":"A simple and rapid LC-MS\/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients","volume":"7","author":"Becher","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2024.127111_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jpba.2017.08.012","article-title":"Simple and rapid LC-MS\/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin","volume":"146","author":"Shibata","year":"2017","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.talanta.2024.127111_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jpba.2007.11.002","article-title":"Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry","volume":"46","author":"Damen","year":"2008","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.talanta.2024.127111_bib27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/molecules26051383","article-title":"Development, validation, and comparison of two mass spectrometry methods (LC-MS\/HRMS and LC-MS\/MS) for the quantification of rituximab in human plasma","volume":"26","author":"Millet","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.talanta.2024.127111_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clinbiochem.2020.10.007","article-title":"Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits","volume":"87","author":"Truffot","year":"2021","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.talanta.2024.127111_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.121889","article-title":"Quantification of nivolumab in human plasma by LC-MS\/HRMS and LC-MS\/MS, comparison with ELISA","volume":"224","author":"Millet","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2024.127111_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/TCRM.S282390","article-title":"Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology","author":"Mancinelli","year":"2021","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"10","key":"10.1016\/j.talanta.2024.127111_bib31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sci."},{"issue":"8","key":"10.1016\/j.talanta.2024.127111_bib32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/ph14080796","article-title":"Cross-validation of a multiplex LC-MS\/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study","volume":"14","author":"Marin","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.talanta.2024.127111_bib33","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00216-011-5527-9","article-title":"Attribution of the discrepancy between ELISA and LC-MS\/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies","volume":"402","author":"Wang","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2024.127111_bib34","first-page":"12","article-title":"ProteinWorks Auto-eXpress Digest","author":"Waters","year":"2018","journal-title":"Kits"},{"key":"10.1016\/j.talanta.2024.127111_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trac.2012.11.015","article-title":"Analysis of biopharmaceutical proteins in biological matrices by LC-MS\/MS I. Sample preparation","volume":"48","author":"Bischoff","year":"2013","journal-title":"TrAC, Trends Anal. Chem."},{"issue":"1","key":"10.1016\/j.talanta.2024.127111_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cells8010012","article-title":"Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients","volume":"8","author":"Gingele","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.talanta.2024.127111_bib37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"issue":"15_supplement","key":"10.1016\/j.talanta.2024.127111_bib38","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.N4.001","article-title":"Pharmacokinetics, pharmacodynamics and exposure-response analyses of ocrelizumab in patients with multiple sclerosis (N4.001)","volume":"92","author":"Kletzl","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.talanta.2024.127111_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/jnnp-2022-330793","article-title":"Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis","volume":"94","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"6","key":"10.1016\/j.talanta.2024.127111_bib40","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.talanta.2024.127111_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.aca.2018.02.040","article-title":"Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS\/MS","volume":"1019","author":"Chiu","year":"2018","journal-title":"Anal. Chim. Acta"},{"issue":"1","key":"10.1016\/j.talanta.2024.127111_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1795492","article-title":"Development and validation of an LC-MS\/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab","volume":"12","author":"Schokker","year":"2020","journal-title":"mAbs"},{"first-page":"45","year":"2022","series-title":"ICH guideline M10 on bioanalytical method validation and study sample analysis","key":"10.1016\/j.talanta.2024.127111_bib43"}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914024014905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914024014905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:28:13Z","timestamp":1733304493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914024014905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"alternative-id":["S0039914024014905"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2024.127111","relation":{},"ISSN":["0039-9140"],"issn-type":[{"type":"print","value":"0039-9140"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A liquid chromatography - Tandem mass spectrometry method for determination of ocrelizumab in serum of patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2024.127111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127111"}}